A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer.
暂无分享,去创建一个
Minetta C. Liu | M. Rivera | J. Kasperbauer | E. Moore | K. Bible | Y. Garces | R. Foote | K. V. Van Abel | D. Price | J. Janus | Jun Yin | M. Neben-Wittich | D. Ma | A. Chintakuntlawar | K. Price | C. Hilger | J. Morris | Mabel Ryder | Erik J Asmus | E. Samb | Crystal R Hilger | J. Morris
[1] C. Lin,et al. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. , 2018, Chest.
[2] A. Garden,et al. Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. , 2018, Thyroid : official journal of the American Thyroid Association.
[3] M. Rivera,et al. Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer , 2017, The Journal of clinical endocrinology and metabolism.
[4] G. Weiss,et al. A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus) , 2017, British Journal of Cancer.
[5] J. Kasperbauer,et al. Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study , 2017, The Journal of clinical endocrinology and metabolism.
[6] A. Garden,et al. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base , 2017, Cancer.
[7] S. Devesa,et al. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013 , 2017, JAMA.
[8] Tae Yong Kim,et al. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area. , 2016, Thyroid : official journal of the American Thyroid Association.
[9] R. McIntyre,et al. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. , 2016, The Journal of clinical endocrinology and metabolism.
[10] S. Mane,et al. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. , 2015, Human molecular genetics.
[11] J. Shah,et al. Anaplastic Thyroid Carcinoma: A 25-year Single-Institution Experience , 2014, Annals of Surgical Oncology.
[12] R. Smallridge,et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. , 2011, Thyroid : official journal of the American Thyroid Association.
[13] J. Hay,et al. Anaplastic thyroid cancer in British Columbia 1985-1999: a population-based study. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).
[14] E. Baudin,et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. , 2004, International Journal of Radiation Oncology, Biology, Physics.
[15] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.